Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal for Immunotherapy of Cancer|November 14, 2024
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse eventsMalek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, et al.
Clinical Genitourinary Cancer|December 8, 2022
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial CarcinomaDimitrios Makrakis, Dimitra Rafailia Bakaloudi, Rafee Talukder, et al.
European Journal of Gastroenterology & Hepatology|January 12, 2026
Risk factors and clinical course of inflammatory bowel disease in patients receiving cancer therapyCristina Natha, Carolina Colli Cruz, Varun Vemulapalli, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Nature|July 8, 2026
Air-permeable hydrogels through viscoelastic phase separation of aerogelsXiao-Yun Yan, Shucong Li, Won Jun Song, et al.
European Urology|April 1, 2019
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate CancerWilliam S Chen, Rahul Aggarwal, Li Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Clinical Genitourinary Cancer|July 1, 2022
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial CarcinomaDimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Clinical Genitourinary Cancer|September 26, 2022
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial CarcinomaRafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, et al.
Pageof 4